Use of RespinPAD in Elderly Patients

Not Applicable

Completed

• Conditions: Acute or Chronic Respiratory Pathologies
• Interventions: Device: Respin Pad; Other: usual treatment

• Registration Number: NCT03607032
• Lead Sponsor: Centre Hospitalier Universitaire de Nice

Brief Summary

Secretive (or obstructive), acute or chronic pathologies are common in an increasing number of elderly patients. The medical teams are confronted with difficulties in the management of these patients: they do not benefit from optimal respiratory physiotherapy, whether manual or mechanical, due to functional deficiencies, cognitive functions that are sometimes limited or poorly adapted equipment.

The objective of this pilot study is to evaluate the effectiveness of a new RespinPAD device in the bronchial de-encapsulation of elderly patients who cannot benefit from optimal physiotherapy compared to conventional treatment (nasal or bucco-tracheal aspiration and aerosols).

The study will include 20 non-dementia patients and 20 dementia patients who will benefit from the use of RespinPAD and 20 patients who will benefit from conventional therapy. All the patients included will be over 70 years old and will be recruited when they are admitted to hospital in the geriatric hospital of the CHU de Nice. They will be included if they present a bronchial obstruction secondary to a respiratory pathology secreting whatever the etiology and for which optimal respiratory physiotherapy is not possible after evaluation by a physiotherapist.

Patients using the RespinPAD device will benefit from a 20-minute session twice daily for 5 days.

The primary endpoint (quantitative criterion) will be the measurement of oxygen consumption (VO2) and carbon dioxide production (VCO2) volumes for each patient included before and after each session of RespinPAD use or conventional treatment for the control group.

Secondary judging criteria will be a heteroassessment of the SEVA (Airway Overcrowding Score), the Borg Scale and the Algoplus or Digital Comfort Scale. For the effectiveness assessment, the SEVA score will allow for a qualitative assessment to complement the primary endpoint. The collection of volumes of secretions, pulse oximeter, mean length of stay, O2 withdrawal time and drug aerosols will also be used to compare results with previous studies. With regard to secondary safety and feasibility criteria, hemodynamic constants, electrocardiogram and the actual duration of the sessions will be recorded.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-02-15
• Study First Submitted QC: 2018-07-23
• Study First Posted: 2018-07-31
• Study Start: 2019-01-04
• Primary Completion: 2020-10-24
• Study Completion: 2020-10-24
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-15
• Last Update Posted: 2023-11-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

• Patient over 70 years of age
• member of the social security system
• hospitalized at the gerontology centre of the CHU de Nice (Cimiez): short geriatric stay, follow-up care and rehabilitation, long-term care unit or EHPAD.
• presenting a clinical bronchial obstruction (auscultatory signs with ronchi type) secondary to a secreting pathology (exacerbation of asthma or chronic obstructive bronchitis, acute bronchitis or acute infectious pneumonitis, repeated swallowing disorders, pulmonary disease of inhalation...) with or without radiological bronchial syndrome.
• for which a respiratory physiotherapy is not effective after expertise of the physiotherapist

Read More

Exclusion Criteria

• a patient who is not hemodynamically stable or who has impaired alertness (glasgow<15) or shows signs of respiratory control (choracic-abdominal sway, costal or superclavicular draft, bronchospasm),
• Patient or trustworthy person who did not complete and sign the consent to participate in the study,
• a patient with chest pain, clinical intracranial hypertension (HIC) greater than 20 mmHg, uncontrolled high blood pressure, dyspnea of a different etiology than bronchial obstruction (a rapid and/or poorly tolerated ACFA, clinical or radiological pleural effusion, empyema, pneumothorax, decompensated heart failure, pericarditis, pericarditis
• The patient cannot benefit from naso-tracheal aspiration,
• End-stage palliative care patient
• patient already participating in another study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
RespinPad and usual treatment	usual treatment	-
only usual treatment	usual treatment	-
RespinPad and usual treatment	Respin Pad	-

Primary Outcome Measures

Name	Time	Method
VO2	17 months	Measurements of oxygen consumption (VO2) (quantitative) volumes on each patient included before and after each RespinPad session, and before and after each conventional treatment for the control group.
VCO2	17 months	Measurements of carbon dioxide production (VCO2) (quantitative) volumes on each patient included before and after each RespinPad session, and before and after each conventional treatment for the control group.

Trial Locations

Locations (1)

Nice Hospital; 🇫🇷 Nice, France